Tag Archives: test

#437733 Video Friday: MIT Media Lab Developing ...

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here’s what we have so far (send us your events!):

AWS Cloud Robotics Summit – August 18-19, 2020 – [Online Conference]
CLAWAR 2020 – August 24-26, 2020 – [Online Conference]
ICUAS 2020 – September 1-4, 2020 – Athens, Greece
ICRES 2020 – September 28-29, 2020 – Taipei, Taiwan
AUVSI EXPONENTIAL 2020 – October 5-8, 2020 – [Online Conference]
IROS 2020 – October 25-29, 2020 – Las Vegas, Nev., USA
ICSR 2020 – November 14-16, 2020 – Golden, Colo., USA
Let us know if you have suggestions for next week, and enjoy today’s videos.

Very impressive local obstacle avoidance at a fairly high speed on a small drone, both indoors and outdoors.

[ FAST Lab ]

Matt Carney writes:

My PhD at MIT Media Lab has been the design and build of a next generation powered prosthesis. The bionic ankle, named TF8, was designed to provide biologically equivalent power and range of motion for plantarflexion-dorsiflexion. This video shows the process of going from a blank sheet of paper to people walking on it. Shown are three different people wearing the robot. About a dozen people have since been able to test the hardware.

[ MIT ]

Thanks Matt!

Exciting changes are coming to the iRobot® Home App. Get ready for new personalized experiences, improved features, and an easy-to-use interface. The update is rolling out over the next few weeks!

[ iRobot ]

MOFLIN is an AI Pet created from a totally new concept. It possesses emotional capabilities that evolve like living animals. With its warm soft fur, cute sounds, and adorable movement, you’d want to love it forever. We took a nature inspired approach and developed a unique algorithm that allows MOFLIN to learn and grow by constantly using its interactions to determine patterns and evaluate its surroundings from its sensors. MOFLIN will choose from an infinite number of mobile and sound pattern combinations to respond and express its feelings. To put it in simple terms, it’s like you’re interacting with a living pet.

You lost me at “it’s like you’re interacting with a living pet.”

[ Kickstarter ] via [ Gizmodo ]

This video is only robotics-adjacent, but it has applications for robotic insects. With a high-speed tracking system, we can now follow insects as they jump and fly, and watch how clumsy (but effective) they are at it.

[ Paper ]

Thanks Sawyer!

Suzumori Endo Lab, Tokyo Tech has developed self-excited pneumatic actuators that can be integrally molded by a 3D printer. These actuators use the “automatic flow path switching mechanism” we have devised.

[ Suzimori Endo Lab ]

Quadrupeds are getting so much better at deciding where to step rather than just stepping where they like and trying not to fall over.

[ RSL ]

Omnidirectional micro aerial vehicles are a growing field of research, with demonstrated advantages for aerial interaction and uninhibited observation. While systems with complete pose omnidirectionality and high hover efficiency have been developed independently, a robust system that combines the two has not been demonstrated to date. This paper presents the design and optimal control of a novel omnidirectional vehicle that can exert a wrench in any orientation while maintaining efficient flight configurations.

[ ASL ]

The latest in smooth humanoid walking from Dr. Guero.

[ YouTube ]

Will robots replace humans one day? When it comes to space exploration, robots are our precursors, gathering data to prepare humans for deep space. ESA robotics engineer Martin Azkarate discusses some of the upcoming missions involving robots and the unique science they will perform in this episode of Meet the Experts.

[ ESA ]

The Multi-robot Systems Group at FEE-CTU in Prague is working on an autonomous drone that detects fires and the shoots an extinguisher capsule at them.

[ MRS ]

This experiment with HEAP (Hydraulic Excavator for Autonomous Purposes) demonstrates our latest research in on-site and mobile digital fabrication with found materials. The embankment prototype in natural granular material was achieved using state of the art design and construction processes in mapping, modelling, planning and control. The entire process of building the embankment was fully autonomous. An operator was only present in the cabin for safety purposes.

[ RSL ]

The Simulation, Systems Optimization and Robotics Group (SIM) of Technische Universität Darmstadt’s Department of Computer Science conducts research on cooperating autonomous mobile robots, biologically inspired robots and numerical optimization and control methods.

[ SIM ]

Starting January 1, 2021, your drone platform of choice may be severely limited by the European Union’s new drone regulations. In this short video, senseFly’s Brock Ryder explains what that means for drone programs and operators and where senseFly drones fit in the EU’s new regulatory framework.

[ SenseFly ]

Nearly every company across every industry is looking for new ways to minimize human contact, cut costs and address the labor crunch in repetitive and dangerous jobs. WSJ explores why many are looking to robots as the solution for all three.

[ WSJ ]

You’ll need to prepare yourself emotionally for this video on “Examining Users’ Attitude Towards Robot Punishment.”

[ ACM ]

In this episode of the AI Podcast, Lex interviews Russ Tedrake (MIT and TRI) about biped locomotion, the DRC, home robots, and more.

[ AI Podcast ] Continue reading

Posted in Human Robots

#437707 Video Friday: This Robot Will Restock ...

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here's what we have so far (send us your events!):

CLAWAR 2020 – August 24-26, 2020 – [Online Conference]
ICUAS 2020 – September 1-4, 2020 – Athens, Greece
ICRES 2020 – September 28-29, 2020 – Taipei, Taiwan
AUVSI EXPONENTIAL 2020 – October 5-8, 2020 – [Online Conference]
IROS 2020 – October 25-29, 2020 – Las Vegas, Nev., USA
CYBATHLON 2020 – November 13-14, 2020 – [Online Event]
ICSR 2020 – November 14-16, 2020 – Golden, Colo., USA
Let us know if you have suggestions for next week, and enjoy today's videos.

Tokyo startup Telexistence has recently unveiled a new robot called the Model-T, an advanced teleoperated humanoid that can use tools and grasp a wide range of objects. Japanese convenience store chain FamilyMart plans to test the Model-T to restock shelves in up to 20 stores by 2022. In the trial, a human “pilot” will operate the robot remotely, handling items like beverage bottles, rice balls, sandwiches, and bento boxes.

With Model-T and AWP, FamilyMart and TX aim to realize a completely new store operation by remoteizing and automating the merchandise restocking work, which requires a large number of labor-hours. As a result, stores can operate with less number of workers and enable them to recruit employees regardless of the store’s physical location.

[ Telexistence ]

Quadruped dance-off should be a new robotics competition at IROS or ICRA.

I dunno though, that moonwalk might keep Spot in the lead…

[ Unitree ]

Through a hybrid of simulation and real-life training, this air muscle robot is learning to play table tennis.

Table tennis requires to execute fast and precise motions. To gain precision it is necessary to explore in this high-speed regimes, however, exploration can be safety-critical at the same time. The combination of RL and muscular soft robots allows to close this gap. While robots actuated by pneumatic artificial muscles generate high forces that are required for e.g. smashing, they also offer safe execution of explosive motions due to antagonistic actuation.

To enable practical training without real balls, we introduce Hybrid Sim and Real Training (HYSR) that replays prerecorded real balls in simulation while executing actions on the real system. In this manner, RL can learn the challenging motor control of the PAM-driven robot while executing ~15000 hitting motions.

[ Max Planck Institute ]

Thanks Dieter!

Anthony Cowley wrote in to share his recent thesis work on UPSLAM, a fast and lightweight SLAM technique that records data in panoramic depth images (just PNGs) that are easy to visualize and even easier to share between robots, even on low-bandwidth networks.

[ UPenn ]

Thanks Anthony!

GITAI’s G1 is the space dedicated general-purpose robot. G1 robot will enable automation of various tasks internally & externally on space stations and for lunar base development.

[ Gitai ]

The University of Michigan has a fancy new treadmill that’s built right into the floor, which proves to be a bit much for Mini Cheetah.

But Cassie Blue won’t get stuck on no treadmill! She goes for a 0.3 mile walk across campus, which ends when a certain someone ran the gantry into Cassie Blue’s foot.

[ Michigan Robotics ]

Some serious quadruped research going on at UT Austin Human Centered Robotics Lab.

[ HCRL ]

Will Burrard-Lucas has spent lockdown upgrading his slightly indestructible BeetleCam wildlife photographing robot.

[ Will Burrard-Lucas ]

Teleoperated surgical robots are becoming commonplace in operating rooms, but many are massive (sometimes taking up an entire room) and are difficult to manipulate, especially if a complication arises and the robot needs to removed from the patient. A new collaboration between the Wyss Institute, Harvard University, and Sony Corporation has created the mini-RCM, a surgical robot the size of a tennis ball that weighs as much as a penny, and performed significantly better than manually operated tools in delicate mock-surgical procedures. Importantly, its small size means it is more comparable to the human tissues and structures on which it operates, and it can easily be removed by hand if needed.

[ Harvard Wyss ]

Yaskawa appears to be working on a robot that can scan you with a temperature gun and then jam a mask on your face?

[ Motoman ]

Maybe we should just not have people working in mines anymore, how about that?

[ Exyn ]

Many current human-robot interactive systems tend to use accurate and fast – but also costly – actuators and tracking systems to establish working prototypes that are safe to use and deploy for user studies. This paper presents an embedded framework to build a desktop space for human-robot interaction, using an open-source robot arm, as well as two RGB cameras connected to a Raspberry Pi-based controller that allow a fast yet low-cost object tracking and manipulation in 3D. We show in our evaluations that this facilitates prototyping a number of systems in which user and robot arm can commonly interact with physical objects.

[ Paper ]

IBM Research is proud to host professor Yoshua Bengio — one of the world’s leading experts in AI — in a discussion of how AI can contribute to the fight against COVID-19.

[ IBM Research ]

Ira Pastor, ideaXme life sciences ambassador interviews Professor Dr. Hiroshi Ishiguro, the Director of the Intelligent Robotics Laboratory, of the Department of Systems Innovation, in the Graduate School of Engineering Science, at Osaka University, Japan.

[ ideaXme ]

A CVPR talk from Stanford’s Chelsea Finn on “Generalization in Visuomotor Learning.”

[ Stanford ] Continue reading

Posted in Human Robots

#437701 Robotics, AI, and Cloud Computing ...

IBM must be brimming with confidence about its new automated system for performing chemical synthesis because Big Blue just had twenty or so journalists demo the complex technology live in a virtual room.

IBM even had one of the journalists choose the molecule for the demo: a molecule in a potential Covid-19 treatment. And then we watched as the system synthesized and tested the molecule and provided its analysis in a PDF document that we all saw in the other journalist’s computer. It all worked; again, that’s confidence.

The complex system is based upon technology IBM started developing three years ago that uses artificial intelligence (AI) to predict chemical reactions. In August 2018, IBM made this service available via the Cloud and dubbed it RXN for Chemistry.

Now, the company has added a new wrinkle to its Cloud-based AI: robotics. This new and improved system is no longer named simply RXN for Chemistry, but RoboRXN for Chemistry.

All of the journalists assembled for this live demo of RoboRXN could watch as the robotic system executed various steps, such as moving the reactor to a small reagent and then moving the solvent to a small reagent. The robotic system carried out the entire set of procedures—completing the synthesis and analysis of the molecule—in eight steps.

Image: IBM Research

IBM RXN helps predict chemical reaction outcomes or design retrosynthesis in seconds.

In regular practice, a user will be able to suggest a combination of molecules they would like to test. The AI will pick up the order and task a robotic system to run the reactions necessary to produce and test the molecule. Users will be provided analyses of how well their molecules performed.

Back in March of this year, Silicon Valley-based startup Strateos demonstrated something similar that they had developed. That system also employed a robotic system to help researchers working from the Cloud create new chemical compounds. However, what distinguishes IBM’s system is its incorporation of a third element: the AI.

The backbone of IBM’s AI model is a machine learning translation method that treats chemistry like language translation. It translates the language of chemistry by converting reactants and reagents to products through the use of Statistical Machine Intelligence and Learning Engine (SMILE) representation to describe chemical entities.

IBM has also leveraged an automatic data driven strategy to ensure the quality of its data. Researchers there used millions of chemical reactions to teach the AI system chemistry, but contained within that data set were errors. So, how did IBM clean this so-called noisy data to eliminate the potential for bad models?

According to Alessandra Toniato, a researcher at IBM Zurichh, the team implemented what they dubbed the “forgetting experiment.”

Toniato explains that, in this approach, they asked the AI model how sure it was that the chemical examples it was given were examples of correct chemistry. When faced with this choice, the AI identified chemistry that it had “never learnt,” “forgotten six times,” or “never forgotten.” Those that were “never forgotten” were examples that were clean, and in this way they were able to clean the data that AI had been presented.

While the AI has always been part of the RXN for Chemistry, the robotics is the newest element. The main benefit that turning over the carrying out of the reactions to a robotic system is expected to yield is to free up chemists from doing the often tedious process of having to design a synthesis from scratch, says Matteo Manica, a research staff member in Cognitive Health Care and Life Sciences at IBM Research Zürich.

“In this demo, you could see how the system is synergistic between a human and AI,” said Manica. “Combine that with the fact that we can run all these processes with a robotic system 24/7 from anywhere in the world, and you can see how it will really help up to speed up the whole process.”

There appear to be two business models that IBM is pursuing with its latest technology. One is to deploy the entire system on the premises of a company. The other is to offer licenses to private Cloud installations.

Photo: Michael Buholzer

Teodoro Laino of IBM Research Europe.

“From a business perspective you can think of having a system like we demonstrated being replicated on the premise within companies or research groups that would like to have the technology available at their disposal,” says Teodoro Laino, distinguished RSM, manager at IBM Research Europe. “On the other hand, we are also pushing at bringing the entire system to a service level.”

Just as IBM is brimming with confidence about its new technology, the company also has grand aspirations for it.

Laino adds: “Our aim is to provide chemical services across the world, a sort of Amazon of chemistry, where instead of looking for chemistry already in stock, you are asking for chemistry on demand.”

< Back to IEEE COVID-19 Resources Continue reading

Posted in Human Robots

#437693 Video Friday: Drone Helps Explore ...

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here's what we have so far (send us your events!):

ICRES 2020 – September 28-29, 2020 – Taipei, Taiwan
AUVSI EXPONENTIAL 2020 – October 5-8, 2020 – [Online Conference]
IROS 2020 – October 25-29, 2020 – Las Vegas, Nev., USA
CYBATHLON 2020 – November 13-14, 2020 – [Online Event]
ICSR 2020 – November 14-16, 2020 – Golden, Colo., USA
Let us know if you have suggestions for next week, and enjoy today's videos.

Clearpath Robotics and Boston Dynamics were obviously destined to partner up with Spot, because Spot 100 percent stole its color scheme from Clearpath, which has a monopoly on yellow and black robots. But seriously, the news here is that thanks to Clearpath, Spot now works seamlessly with ROS.

[ Clearpath Robotics ]

A new video created by Swisscom Ventures highlights a research expedition sponsored by Moncler to explore the deepest ice caves in the world using Flyability’s Elios drone. […] The expedition was sponsored by apparel company Moncler and took place over two weeks in 2018 on the Greenland ice sheet, the second largest body of ice in the world after Antarctica. Research focused on an area about 80 kilometers east of Kangerlussuaq, where scientists wanted to study the movement of water deep underground to better understand the effects of climate change on the melting ice.

[ Flyability ]

Shane Wighton of the “Stuff Made Here” YouTube channel, whose terrifying haircut machine we featured a few months ago, has improved on his robotic basketball hoop. It’s actually more than an improvement: It’s a complete redesign that nearly drove Wighton insane. But the result is pretty cool. It’s fun to watch him building a highly complicated system while always seeking simple and elegant designs for its components.

[ Stuff Made Here ]

SpaceX rockets are really just giant, explosion-powered drones that go into space sometimes. So let's watch more videos of them! This one is sped up, and puts a flight into just a couple of minutes.

[ SpaceX ]

Neato Robotics makes some solid autonomous vacuums, and these incremental upgrades feature improved battery life and better air filters.

[ Neato Robotics ]

A full-scale engineering model of NASA's Perseverance Mars rover now resides in a garage facing the Mars Yard at NASA's Jet Propulsion Laboratory in Southern California.

This vehicle system test bed rover (VSTB) is also known as OPTIMISM, which stands for Operational Perseverance Twin for Integration of Mechanisms and Instruments Sent to Mars. OPTIMISM was built in a warehouselike assembly room near the Mars Yard – an area that simulates the Red Planet's rocky surface. The rover helps the mission test hardware and software before it’s transmitted to the real rover on Mars. OPTIMISM will share the space with the Curiosity rover's twin MAGGIE.

[ JPL ]

Heavy asset industries like shipping, oil and gas, and manufacturing are grounded in repetitive tasks like locating items on large industrial sites — a tedious task that can take as long 45 minutes to find critical items like a forklift in an area that spans the size of multiple football fields. Not only is this work boring, it’s dangerous and inefficient. Robots like Spot, however, love this sort of work.

Spot can provide real-time updates on the location of assets and complete other mundane tasks. In this case, Spot is using software from Cognite to roam the vast shipyard to locate and manage more than 100,000 assets stored across the facility. What used to take humans hours can be managed on an ongoing basis by Spot — leaving employees to focus on more strategic tasks.

[ Cognite ]

The KNEXT Barista system helps high volume premium coffee providers who want to offer artisan coffee specialities in consistent quality.

[ Kuka ]

In this paper, we study this idea of generality in the locomotion domain. We develop a learning framework that can learn sophisticated locomotion behavior for a wide spectrum of legged robots, such as bipeds, tripeds, quadrupeds and hexapods, including wheeled variants. Our learning framework relies on a data-efficient, off-policy multi-task RL algorithm and a small set of reward functions that are semantically identical across robots.

[ DeepMind ]

Thanks Dave!

Even though it seems like the real risk of COVID is catching it from another person, robotics companies are doing what they can with UVC disinfecting systems.

[ BlueBotics ]

Aeditive develop robotic 3D printing solutions for the production of concrete components. At the heart of their production plant are two large robots that cooperate to manufacture the component. The automation technology they build on is a robotic shotcrete process. During this process, they apply concrete layer by layer and thus manufacture complete components. This means that their customers no longer dependent on formwork, which is expensive and time-consuming to create. Instead, their customers can manufacture components directly on a steel pallet without these moulds.

[ Aeditive ]

Something BIG is coming next month from Robotiq!

My guess: an elephant.

[ Robotiq ]

TurtleBot3 is a great little home robot, as long as you have a TurtleBot3-sized home.

[ Robotis ]

How do you calculate the coordinated movements of two robot arms so they can accurately guide a highly flexible tool? ETH researchers have integrated all aspects of the optimisation calculations into an algorithm. The hot-​wire cutter will be used, among other things, to develop building blocks for a mortar-​free structure.

[ ETH Zurich ]

And now, this.

[ RobotStart ] Continue reading

Posted in Human Robots

#437673 Can AI and Automation Deliver a COVID-19 ...

Illustration: Marysia Machulska

Within moments of meeting each other at a conference last year, Nathan Collins and Yann Gaston-Mathé began devising a plan to work together. Gaston-Mathé runs a startup that applies automated software to the design of new drug candidates. Collins leads a team that uses an automated chemistry platform to synthesize new drug candidates.

“There was an obvious synergy between their technology and ours,” recalls Gaston-Mathé, CEO and cofounder of Paris-based Iktos.

In late 2019, the pair launched a project to create a brand-new antiviral drug that would block a specific protein exploited by influenza viruses. Then the COVID-19 pandemic erupted across the world stage, and Gaston-Mathé and Collins learned that the viral culprit, SARS-CoV-2, relied on a protein that was 97 percent similar to their influenza protein. The partners pivoted.

Their companies are just two of hundreds of biotech firms eager to overhaul the drug-discovery process, often with the aid of artificial intelligence (AI) tools. The first set of antiviral drugs to treat COVID-19 will likely come from sifting through existing drugs. Remdesivir, for example, was originally developed to treat Ebola, and it has been shown to speed the recovery of hospitalized COVID-19 patients. But a drug made for one condition often has side effects and limited potency when applied to another. If researchers can produce an ­antiviral that specifically targets SARS-CoV-2, the drug would likely be safer and more effective than a repurposed drug.

There’s one big problem: Traditional drug discovery is far too slow to react to a pandemic. Designing a drug from scratch typically takes three to five years—and that’s before human clinical trials. “Our goal, with the combination of AI and automation, is to reduce that down to six months or less,” says Collins, who is chief strategy officer at SRI Biosciences, a division of the Silicon Valley research nonprofit SRI International. “We want to get this to be very, very fast.”

That sentiment is shared by small biotech firms and big pharmaceutical companies alike, many of which are now ramping up automated technologies backed by supercomputing power to predict, design, and test new antivirals—for this pandemic as well as the next—with unprecedented speed and scope.

“The entire industry is embracing these tools,” says Kara Carter, president of the International Society for Antiviral Research and executive vice president of infectious disease at Evotec, a drug-discovery company in Hamburg. “Not only do we need [new antivirals] to treat the SARS-CoV-2 infection in the population, which is probably here to stay, but we’ll also need them to treat future agents that arrive.”

There are currentlyabout 200 known viruses that infect humans. Although viruses represent less than 14 percent of all known human pathogens, they make up two-thirds of all new human pathogens discovered since 1980.

Antiviral drugs are fundamentally different from vaccines, which teach a person’s immune system to mount a defense against a viral invader, and antibody treatments, which enhance the body’s immune response. By contrast, anti­virals are chemical compounds that directly block a virus after a person has become infected. They do this by binding to specific proteins and preventing them from functioning, so that the virus cannot copy itself or enter or exit a cell.

The SARS-CoV-2 virus has an estimated 25 to 29 proteins, but not all of them are suitable drug targets. Researchers are investigating, among other targets, the virus’s exterior spike protein, which binds to a receptor on a human cell; two scissorlike enzymes, called proteases, that cut up long strings of viral proteins into functional pieces inside the cell; and a polymerase complex that makes the cell churn out copies of the virus’s genetic material, in the form of single-stranded RNA.

But it’s not enough for a drug candidate to simply attach to a target protein. Chemists also consider how tightly the compound binds to its target, whether it binds to other things as well, how quickly it metabolizes in the body, and so on. A drug candidate may have 10 to 20 such objectives. “Very often those objectives can appear to be anticorrelated or contradictory with each other,” says Gaston-Mathé.

Compared with antibiotics, antiviral drug discovery has proceeded at a snail’s pace. Scientists advanced from isolating the first antibacterial molecules in 1910 to developing an arsenal of powerful antibiotics by 1944. By contrast, it took until 1951 for researchers to be able to routinely grow large amounts of virus particles in cells in a dish, a breakthrough that earned the inventors a Nobel Prize in Medicine in 1954.

And the lag between the discovery of a virus and the creation of a treatment can be heartbreaking. According to the World Health Organization, 71 million people worldwide have chronic hepatitis C, a major cause of liver cancer. The virus that causes the infection was discovered in 1989, but effective antiviral drugs didn’t hit the market until 2014.

While many antibiotics work on a range of microbes, most antivirals are highly specific to a single virus—what those in the business call “one bug, one drug.” It takes a detailed understanding of a virus to develop an antiviral against it, says Che Colpitts, a virologist at Queen’s University, in Canada, who works on antivirals against RNA viruses. “When a new virus emerges, like SARS-CoV-2, we’re at a big disadvantage.”

Making drugs to stop viruses is hard for three main reasons. First, viruses are the Spartans of the pathogen world: They’re frugal, brutal, and expert at evading the human immune system. About 20 to 250 nanometers in diameter, viruses rely on just a few parts to operate, hijacking host cells to reproduce and often destroying those cells upon departure. They employ tricks to camouflage their presence from the host’s immune system, including preventing infected cells from sending out molecular distress beacons. “Viruses are really small, so they only have a few components, so there’s not that many drug targets available to start with,” says Colpitts.

Second, viruses replicate quickly, typically doubling in number in hours or days. This constant copying of their genetic material enables viruses to evolve quickly, producing mutations able to sidestep drug effects. The virus that causes AIDS soon develops resistance when exposed to a single drug. That’s why a cocktail of antiviral drugs is used to treat HIV infection.

Finally, unlike bacteria, which can exist independently outside human cells, viruses invade human cells to propagate, so any drug designed to eliminate a virus needs to spare the host cell. A drug that fails to distinguish between a virus and a cell can cause serious side effects. “Discriminating between the two is really quite difficult,” says Evotec’s Carter, who has worked in antiviral drug discovery for over three decades.

And then there’s the money barrier. Developing antivirals is rarely profitable. Health-policy researchers at the London School of Economics recently estimated that the average cost of developing a new drug is US $1 billion, and up to $2.8 billion for cancer and other specialty drugs. Because antivirals are usually taken for only short periods of time or during short outbreaks of disease, companies rarely recoup what they spent developing the drug, much less turn a profit, says Carter.

To change the status quo, drug discovery needs fresh approaches that leverage new technologies, rather than incremental improvements, says Christian Tidona, managing director of BioMed X, an independent research institute in Heidelberg, Germany. “We need breakthroughs.”

Putting Drug Development on Autopilot
Earlier this year, SRI Biosciences and Iktos began collaborating on a way to use artificial intelligence and automated chemistry to rapidly identify new drugs to target the COVID-19 virus. Within four months, they had designed and synthesized a first round of antiviral candidates. Here’s how they’re doing it.

1/5

STEP 1: Iktos’s AI platform uses deep-learning algorithms in an iterative process to come up with new molecular structures likely to bind to and disable a specific coronavirus protein. Illustrations: Chris Philpot

2/5

STEP 2: SRI Biosciences’s SynFini system is a three-part automated chemistry suite for producing new compounds. Starting with a target compound from Iktos, SynRoute uses machine learning to analyze and optimize routes for creating that compound, with results in about 10 seconds. It prioritizes routes based on cost, likelihood of success, and ease of implementation.

3/5

STEP 3: SynJet, an automated inkjet printer platform, tests the routes by printing out tiny quantities of chemical ingredients to see how they react. If the right compound is produced, the platform tests it.

4/5

STEP 4: AutoSyn, an automated tabletop chemical plant, synthesizes milligrams to grams of the desired compound for further testing. Computer-selected “maps” dictate paths through the plant’s modular components.

5/5

STEP 5: The most promising compounds are tested against live virus samples.

Previous
Next

Iktos’s AI platform was created by a medicinal chemist and an AI expert. To tackle SARS-CoV-2, the company used generative models—deep-learning algorithms that generate new data—to “imagine” molecular structures with a good chance of disabling a key coronavirus protein.

For a new drug target, the software proposes and evaluates roughly 1 million compounds, says Gaston-Mathé. It’s an iterative process: At each step, the system generates 100 virtual compounds, which are tested in silico with predictive models to see how closely they meet the objectives. The test results are then used to design the next batch of compounds. “It’s like we have a very, very fast chemist who is designing compounds, testing compounds, getting back the data, then designing another batch of compounds,” he says.

The computer isn’t as smart as a human chemist, Gaston-Mathé notes, but it’s much faster, so it can explore far more of what people in the field call “chemical space”—the set of all possible organic compounds. Unexplored chemical space is huge: Biochemists estimate that there are at least 1063 possible druglike molecules, and that 99.9 percent of all possible small molecules or compounds have never been synthesized.

Still, designing a chemical compound isn’t the hardest part of creating a new drug. After a drug candidate is designed, it must be synthesized, and the highly manual process for synthesizing a new chemical hasn’t changed much in 200 years. It can take days to plan a synthesis process and then months to years to optimize it for manufacture.

That’s why Gaston-Mathé was eager to send Iktos’s AI-generated designs to Collins’s team at SRI Biosciences. With $13.8 million from the Defense Advanced Research Projects Agency, SRI Biosciences spent the last four years automating the synthesis process. The company’s automated suite of three technologies, called SynFini, can produce new chemical compounds in just hours or days, says Collins.

First, machine-learning software devises possible routes for making a desired molecule. Next, an inkjet printer platform tests the routes by printing out and mixing tiny quantities of chemical ingredients to see how they react with one another; if the right compound is produced, the platform runs tests on it. Finally, a tabletop chemical plant synthesizes milligrams to grams of the desired compound.

Less than four months after Iktos and SRI Biosciences announced their collaboration, they had designed and synthesized a first round of antiviral candidates for SARS-CoV-2. Now they’re testing how well the compounds work on actual samples of the virus.

Out of 10
63 possible druglike molecules, 99.9 percent have never been synthesized.

Theirs isn’t the only collaborationapplying new tools to drug discovery. In late March, Alex Zhavoronkov, CEO of Hong Kong–based Insilico Medicine, came across a YouTube video showing three virtual-reality avatars positioning colorful, sticklike fragments in the side of a bulbous blue protein. The three researchers were using VR to explore how compounds might bind to a SARS-CoV-2 enzyme. Zhavoronkov contacted the startup that created the simulation—Nanome, in San Diego—and invited it to examine Insilico’s ­AI-generated molecules in virtual reality.

Insilico runs an AI platform that uses biological data to train deep-learning algorithms, then uses those algorithms to identify molecules with druglike features that will likely bind to a protein target. A four-day training sprint in late January yielded 100 molecules that appear to bind to an important SARS-CoV-2 protease. The company recently began synthesizing some of those molecules for laboratory testing.

Nanome’s VR software, meanwhile, allows researchers to import a molecular structure, then view and manipulate it on the scale of individual atoms. Like human chess players who use computer programs to explore potential moves, chemists can use VR to predict how to make molecules more druglike, says Nanome CEO Steve McCloskey. “The tighter the interface between the human and the computer, the more information goes both ways,” he says.

Zhavoronkov sent data about several of Insilico’s compounds to Nanome, which re-created them in VR. Nanome’s chemist demonstrated chemical tweaks to potentially improve each compound. “It was a very good experience,” says Zhavoronkov.

Meanwhile, in March, Takeda Pharmaceutical Co., of Japan, invited Schrödinger, a New York–based company that develops chemical-simulation software, to join an alliance working on antivirals. Schrödinger’s AI focuses on the physics of how proteins interact with small molecules and one another.

The software sifts through billions of molecules per week to predict a compound’s properties, and it optimizes for multiple desired properties simultaneously, says Karen Akinsanya, chief biomedical scientist and head of discovery R&D at Schrödinger. “There’s a huge sense of urgency here to come up with a potent molecule, but also to come up with molecules that are going to be well tolerated” by the body, she says. Drug developers are seeking compounds that can be broadly used and easily administered, such as an oral drug rather than an intravenous drug, she adds.

Schrödinger evaluated four protein targets and performed virtual screens for two of them, a computing-intensive process. In June, Google Cloud donated the equivalent of 16 million hours of Nvidia GPU time for the company’s calculations. Next, the alliance’s drug companies will synthesize and test the most promising compounds identified by the virtual screens.

Other companies, including Amazon Web Services, IBM, and Intel, as well as several U.S. national labs are also donating time and resources to the Covid-19 High Performance Computing Consortium. The consortium is supporting 87 projects, which now have access to 6.8 million CPU cores, 50,000 GPUs, and 600 petaflops of computational resources.

While advanced technologies could transform early drug discovery, any new drug candidate still has a long road after that. It must be tested in animals, manufactured in large batches for clinical trials, then tested in a series of trials that, for antivirals, lasts an average of seven years.

In May, the BioMed X Institute in Germany launched a five-year project to build a Rapid Antiviral Response Platform, which would speed drug discovery all the way through manufacturing for clinical trials. The €40 million ($47 million) project, backed by drug companies, will identify ­outside-the-box proposals from young scientists, then provide space and funding to develop their ideas.

“We’ll focus on technologies that allow us to go from identification of a new virus to 10,000 doses of a novel potential therapeutic ready for trials in less than six months,” says BioMed X’s Tidona, who leads the project.

While a vaccine will likely arrive long before a bespoke antiviral does, experts expect COVID-19 to be with us for a long time, so the effort to develop a direct-acting, potent antiviral continues. Plus, having new antivirals—and tools to rapidly create more—can only help us prepare for the next pandemic, whether it comes next month or in another 102 years.

“We’ve got to start thinking differently about how to be more responsive to these kinds of threats,” says Collins. “It’s pushing us out of our comfort zones.”

This article appears in the October 2020 print issue as “Automating Antivirals.” Continue reading

Posted in Human Robots